# In vitro characterization of the catalytic domain of human histone deacetylase 5

**Authors:** Christian Mammen, Fenja M. Hornung, Christian Anzenhofer, Julia Schumacher, Jens Reiners, Jingyu Li, Flaminia Mazzone, Florestan L. Bilsing, Matthias U. Kassack, Thomas Kurz, Sander H. J. Smits

PMC · DOI: 10.1038/s41598-026-37633-5 · Scientific Reports · 2026-02-27

## TL;DR

This study examines the activity and inhibition of HDAC5, a protein linked to disease, to help develop more targeted drugs with fewer side effects.

## Contribution

The paper provides new insights into the catalytic behavior of HDAC5 and its inhibition by TFMO-based compounds.

## Key findings

- The catalytic domain of HDAC5 was characterized in vitro.
- FFK24 and NT160 inhibit HDAC5 with a TFMO zinc-binding group.
- Findings support developing selective inhibitors for class IIa HDACs.

## Abstract

Both histone acetyltransferases (HATs) and histone deacetylases (HDACs) control the acetylation state of conserved lysine residues in histone tails. Thereby, modulating chromatin structure and gene transcription. Disturbance of this precisely balanced acetylation state contributes to neuronal, cardiovascular, muscle degenerative, autoimmune diseases and cancer. To restore this delicate balance, HDAC inhibitors (HDACi) are employed. However, employing pan-HDAC inhibitors, that target a broad spectrum of HDACs, often leads to significant side effects. Therefore, the development of isoform specific inhibitors is urgently needed. Among the HDAC family, class IIa HDACs, particularly HDAC5, have emerged as promising drug targets due to their tissue-specific expression patterns and presence in large regulatory complexes. Recent progress in selective class IIa HDAC inhibition has led to the development of novel HDACi that contain a 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO) zinc-binding group (ZBG) to interact with the Zn²⁺ ion in the active site, avoiding the drawbacks associated with promiscuous hydroxamic acid–based HDACi. This study focuses on the in vitro characterization of the catalytic domain of human HDAC5 and its inhibition by the TFMO-based HDACi FFK24 and NT160. Our findings contribute to a better biochemical understanding of the kinetic parameters of HDAC5 activity and support the development of selective inhibitors targeting class IIa HDACs.

The online version contains supplementary material available at 10.1038/s41598-026-37633-5.

## Linked entities

- **Proteins:** HDA05 (histone deacetylase 5), HDAC5 (histone deacetylase 5)
- **Chemicals:** NT160 (PubChem CID 71230992), 5-(trifluoromethyl)-1,2,4-oxadiazole (PubChem CID 20297539)
- **Diseases:** cancer (MONDO:0004992)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** NCOR2 (nuclear receptor corepressor 2) [NCBI Gene 9612] {aka CTG26, N-CoR2, SMAP270, SMRT, SMRTE, SMRTE-tau}, HDAC3 (histone deacetylase 3) [NCBI Gene 8841] {aka HD3, KDAC3, RPD3, RPD3-2}, YY1 (YY1 transcription factor) [NCBI Gene 7528] {aka DELTA, GADEVS, INO80S, NF-E1, UCRBP, YIN-YANG-1}, HDAC5 (histone deacetylase 5) [NCBI Gene 10014] {aka HD5, NY-CO-9}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, MXD1 (MAX dimerization protein 1) [NCBI Gene 4084] {aka BHLHC58, MAD, MAD1}, HDAC4 (histone deacetylase 4) [NCBI Gene 9759] {aka AHO3, BDMR, HA6116, HD4, HDAC-4, HDAC-A}, HDAC11 (histone deacetylase 11) [NCBI Gene 79885] {aka HD11}, MEF2A (myocyte enhancer factor 2A) [NCBI Gene 4205] {aka ADCAD1, RSRFC4, RSRFC9, mef2}, HDAC7 (histone deacetylase 7) [NCBI Gene 51564] {aka HD7, HD7A, HDAC7A}, NCOR1 (nuclear receptor corepressor 1) [NCBI Gene 9611] {aka N-CoR, N-CoR1, PPP1R109, TRAC1, hN-CoR}, HDAC8 (histone deacetylase 8) [NCBI Gene 55869] {aka CDA07, CDLS5, HD8, HDACL1, KDAC8, MRXS6}
- **Diseases:** neuronal, cardiovascular, muscle degenerative, (MESH:D002318), immune disorders (MESH:D007154), cardiac hypertrophy (MESH:D006332), neurodegeneration (MESH:D019636), cancer (MESH:D009369), autoimmune diseases (MESH:D001327)
- **Chemicals:** vorinostat (MESH:D000077337), Hepes (MESH:D006531), (Tfa) (-), ZnCl2 (MESH:C016837), IPTG (MESH:D007544), DMSO (MESH:D004121), KCl (MESH:D011189), hydrogen (MESH:D006859), Salt (MESH:D012492), phosphate (MESH:D010710), Osimertinib (MESH:C000596361), Zn (MESH:D015032), metal (MESH:D008670), MgCl2 (MESH:D015636), Proline (MESH:D011392), 3H (MESH:D014316), NaCl (MESH:D012965), hydroxamic acid (MESH:D006877), histidine (MESH:D006639), LMK235 (MESH:C000630714), leucine (MESH:D007930), tyrosine (MESH:D014443), imidazole (MESH:C029899), water (MESH:D014867), acrylamide (MESH:D020106), kanamycin (MESH:D007612), DTT (MESH:D004229), SDS (MESH:D012967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Escherichia coli (E. coli, species) [taxon 562], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** tyrosine to histidine, H843Y, H1006, H976Y, H1006Y, R 300 K
- **Cell lines:** -8xHis — Xenopus laevis (African clawed frog), Spontaneously immortalized cell line (CVCL_4564)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953687/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953687/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953687/full.md

---
Source: https://tomesphere.com/paper/PMC12953687